Albany, NY, Feb. 16, 2018 --
The global thyroid gland disorders treatment market had a valuation of US$1,954.7 mn in 2016 and is estimated to rise to a valuation of US$2,609.9 mn by 2025, expanding at a CAGR of 3.3% from 2017 to 2025.
Levothyroxine to Remain Most Popular Drug for Treating Hypothyroidism
On the basis of disorders, the global thyroid gland disorders treatment market has been categorized into hypothyroidism and hyperthyroidism. The hypothyroidism segment studies Levothyroxine and Liothyronine drug classes. Of these, the segment of Levothyroxine drug class accounted for nearly 94.6% share of the hypothyroidism treatment market in 2016 and is likely to remain dominant during the forecast period.
Request to View Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3113
Geographically, the market in North America is presently the dominant regional market for thyroid gland disorders treatment. The rising incidence rate of thyroid disorders in the region is the biggest factor emphasizing the need for effective treatments. The American Thyroid Association states that nearly 20,000,000 Americans are suffering from thyroid disorders and nearly 60% of this figure are unaware of the condition due to the non-specific nature of symptoms.
Introduction of Innovative Treatment Methods to Help Market Pick Pace
The global market for thyroid gland disorder treatment is likely to witness a steady rise in patient population across developed as well as developing economies. Factors such as sedentary lifestyle, rising pool of geriatrics, which is a demographic more susceptible to thyroid gland disorders, and an increased rate of prevalence of autoimmune diseases such as Grave’s disease and Hashimoto's thyroiditis are primarily contributing to the increased patient population for thyroid gland disorders. The rising patient pool and the unresolved issue of iodine deficiency in diets of people across several emerging economies can also be considered some of the leading factors spelling growth for the market.
Download PDF Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3113
Factors such as the introduction of innovative therapeutic options from leading pharmaceutical companies, increasing awareness among people about the available treatments, and rising disposable incomes and affordability of generic or branded pharmaceutical formulations in emerging economies are also driving the market. However, the easy availability of generic drugs and high preference of patients to alternative therapies such as thyroid surgery and herbal medicines could hamper the growth prospects of the market to a certain extent.
The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of thyroid gland disorder patients across the globe, preference to alternative treatment methods brings down the growth prospects of companies operating in the market. Nevertheless, with innovative marketing strategies and attempts at improving awareness among patients regarding the benefits of popular drugs could help companies strengthen their positions in the global thyroid gland disorders treatment market.
Buy Thyroid Gland Disorder Treatment Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=3113<ype=S
Some of the leading companies in the market are Merck KGaA, Takeda Pharmaceutical Company Limited, Pfizer, Inc., ALLERGAN, Novartis AG, AbbVie Inc., Sanofi S.A., Lannett Company, Inc., Aspen, and Mylan N.V.
About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Contact Us
Nachiket Ghumare
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany, NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com
Research Blog: http://theglobalhealthnews.com/


Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
FTC Questions Apple News Over Alleged Bias Against Conservative Media
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 



